Summary Doxorubicin accumulation defects in multidrug reistant tumour cells are generally small in comparison to the resistance factors. Therefore additional mechanisms must be operative. In this paper we show by a quantitative approach that doxorubicin resistance in several P-glycoprotein-positive non-small cell lung cancer and breast cancer multidrug resistant cell lines can be explained by a summation of accumulation defect and alterations in the efficacy of the drug once present in the cell. This alteration of efficacy was partly due to changes in intracellular drug localisation, characterised by decreased nuclear/cytoplasmic doxorubicin fluorescence ratios (N/C-ratios). N/C-ratios were 2.8-3.6 in sensitive cells, 0.1-0.4 in cells with high (>70-fold) levels of doxorubicin resistance and 1.2 and 1.9 in cells with low or intermediate (7.5 and 24-fold, respectively) levels of doxorubicin resistance. The change of drug efficacy was reflected by an increase in the total amount of doxorubicin present in the cell at equitoxic (IC50) concentrations. N/C ratios in highly resistant P-glycoprotein-containing cells could be increased with the resistance modifier verapamil to values of 1.3-2.7, a process that was paralleled by a decrease of the cellular doxorubicin amounts present at IC50. At the low to moderate residual levels of resistance, obtained with different concentrations of verapamil, a linear relationship between IC50 and cellular doxorubicin amounts determined at IC50 was found. This shows that at this stage of residual resistance, extra reversal by verapamil should be explained by further increase of drug efficacy rather than by increase of cellular drug accumulation. A similar relationship was found for Pglycoprotein-negative MDR cells with low levels of resistance. Since in these cells N/C ratios could not be altered, verapamil-induced decrease of IC50 must be due to increased drug efficacy by action on as yet unidentified targets. Although the IC50 of sensitive human cells cannot be reached with resistance modifiers, when using these relationships it can be shown by extrapolation that cellular and nuclear doxorubicin amounts at IC50 at complete reversal of resistance were the same as in sensitive cells. It is concluded that doxorubicin resistance factors for multidrug resistant cells can for a large part, and in the case of P-glycoprotein-containing cells probably fully, be accounted for by decreased amounts of drug at nuclear targets, which in turn is characterised by two processes only: decreased cellular accumulation and a shift in the ratio nuclear drug/cytoplasmic drug.
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Expression of the putative drug efflux pump P-glycoprotein in multidrug resistant (MDR) cells results in lower drug accumulation than in the corresponding parent cells (Bradley et al., 1988) . Reduced drug accumulation may also be a parameter of drug resistance for some (Coley et al., 1991; Haber et al., 1989; Hindenburg et al., 1989; Kuiper et al., 1990; McGrath & Center, 1988; Slapak et al., 1990; Slovak et al., 1988; Taylor et al., 1991) but not for all (Cole et al., 1991; Danks et al., 1987; Harker et al., 1989; McGrath et al., 1989 ) MDR cells which do not overexpress P-glycoprotein. Effective modulation of multidrug resistance is possible in Pglycoprotein containing cells with compounds which exhibit different structural features (Zamora et al., 1988) and it is attributed to increases in cellular drug accumulation resulting from inhibition of drug efflux (Bradley et al., 1988) . Modulation of non-P-glycoprotein mediated MDR and accumulation defects by verapamil and other Pgp modulators, however, seems to be less efficient than for P-glycoprotein mediated MDR (Cole et al., 1989; Coley et al., 1991; Harker et al., 1989; Kuiper et al., 1990; Schuurhuis et al., 1991; Slovak et al., 1988; Taylor et al., 1991) .
It is known that changes in drug accumulation can not fully account for anthracycline resistance in many MDR cells (evidence reviewed by Schuurhuis et al., 1989a) . Such con-siderations have led to the suggestion that other mechanisms must contribute to the MDR phenotype. One of the possibilities would be that enzymes, involved in the detoxification of oxygen-derived free radicals generated by semiquinone compounds like doxorubicin, such as glutathione transferase and glutathione peroxidase, contribute to anthracycline resistance in MDR cells Cowan et al., 1986) . MDR human breast cancer MCF-7ADR cells have been studied in depth as to this and it was found that doxorubicin-induced oxygen free radical formation was strongly reduced compared to sensitive cells (Sinha et al., 1987) . Further, changes in levels and/or activity of topoisomerase II may contribute to anthracycline and VP-16-213 resistance (Beck, 1989) . Another important phenomenon associated with MDR is an altered intracellular drug distribution. Several studies now have shown that the development of MDR is associated with a relative shift of doxorubicin or daunorubicin fluorescence from the nucleus to the cytoplasm Gervasoni et al., 1991; Gigli et al., 1989; Hindenburg et al., 1987 Hindenburg et al., , 1989 Schuurhuis et al., 1989a Schuurhuis et al., , 1991 Willingham et al., 1986) . In previous work with Chinese hamster ovarian cells we have argued that this shift may contribute for an important part to the ineffectiveness of anthracyclines in MDR cells (Schuurhuis et al., 1989a) .
We now extend these drug distribution studies using various human MDR cells, including MCF-7ADR cells. With a simple mathematical approach we show that doxorubicin resistance in these P-glycoprotein-containing cells is determined mainly by reduced access to nuclear targets which in turn is characterised by two factors only: reduced drug accumulation and altered subcellular drug distribution.
Thereby the need is excluded to postulate that other mechanisms contribute significantly to resistance. In addition, Br. J. Cancer (1993), 68, 898-908 '." Macmillan Press Ltd., 1993 reversal of resistance in P-glycoprotein/MDR by verapamil is related to effects on these factors. It is further shown that in non-P-glycoprotein/MDR cell lines verapamil exerts part of its effects via a third mechanism different from drug accumulation or distribution. Part of this work has been presented in preliminary form at the 80th Annual Meeting of the American Association for Cancer Research (Schuurhuis et al., 1989b and the SW-1573/2R30 cells, which were selected independently. SW-1573/2R30 cells showed instable resistance and finally resulted in the SW-1573/2R50 cells described earlier Kuiper et al., 1990) . The partially revertant cell line SW-1 573/1 R500-0 was obtained by culturing SW-1573/1 R500 cells in drug-free medium as described Fairchild et al., 1987; Kuiper et al., 1990; Scheper et al., 1988) .
Drug cytotoxicity
Cytostatic effects were assessed essentialy as described previously (Schuurhuis et al., 1987 Drug accumulation Log-phase trypsinised cells were suspended in growth medium without NaHCO3 and phenol red but containing 20 mM HEPES, pH 7.4. Cellular doxorubicin accumulation was measured with [14-'4C] doxorubicin after a 2 h incubation period at 37°C as described (Schuurhuis et al., 1987) Table I ). Cytoplasmic doxorubicin (dox,) was calculated by subtracting the fixed value of 8 pmol 106 cells from the total cellular doxorubicin amounts measured at each IC5o value using radiolabelled doxorubicin (shown under Results in Figure 6 ).
Quantification of drug distribution with laser scan microscopy Quantification of ratios of nuclear doxorubicin fluorescence/ cytoplasmic doxorubicin fluorescence (N/C ratio) with laser scan microscopy and image analysis was performed as described (De Lange et al., 1992; Schuurhuis et al., 1989a) . Adhered MDR and sensitive cells were incubated for 2 h at 37°C at the same concentrations of doxorubicin and/or verapamil that would result in the different IC50 values found in the cytotoxicity assay. For each treatment in a particular experiment 30-50 cells were measured unless indicated otherwise. Total nuclear amounts of doxorubicin were calculated from ratios nuclear doxorubicin/cytoplasmic doxorubicin (N/ C fluorescence ratios, but now corrected for doxorubicin fluorescence quenching by DNA as outlined in the next paragraph) and from [14-'4C] doxorubicin accumulation experiments (giving total cellular doxorubicin amounts) at the doxorubicin and verapamil concentrations of interest.
For direct comparison of relative fluorescence signals in AUXB1 and CHRC5 cells, these cells were allowed to grow on petri dishes in close proximity. This enabled fluorescence recording under the same optical and instrumental conditions. Fluorescence was recorded in at least ten cells in each experiment.
Quenching of doxorubicinfluorescence In order to be able to calculate total nuclear amounts of doxorubicin in intact cells using N/C doxorubicin fluorescence ratios and total cellular amounts as determined with radiolabelled doxorubicin (see previous paragraph), the percentage fluorescence quenching in nuclei needs to be determined. For that purpose isolated nuclei of AUXB1 and CHRC5 cells were prepared by incubating intact cells in hypotonic medium (10 mM Tris.HCI containing 2 mM MgCl2, pH 7.6) for 30 min on ice and subsequent homogenising by pottering. The nuclei were resuspended in growth medium (see under Drug accumulation). The fluorescence signal of 2 jLM doxorubicin in medium of 37°C in a 1 ml cuvet (Io) was determined using a spectrofluorometer (FluoroMaxTM from SPEX Industries, Edison, NJ). Aliquots of nuclei (3.107 ml-) were added to the cuvet. The fluorescence signal decreased as a result of quenching due to intercalation into DNA. Extra aliquots of nuclei were added until the fluorescence signal (originating partly from nuclei-associated and partly from some remaining extra-nuclear fluorescence) had stabilised (I,). The percentage quenching of doxorubicin in the nuclei could be calculated from the decrease of the initial fluorescence of doxorubicin. The fluorescence signal was corrected for (i) the autofluorescence of the particular number of nuclei used (12) and (ii) the remaining extranuclear doxorubicin fluorescence (13), which was determined by centrifuging the nuclei in the cuvet (without washing) and measuring the fluorescence of the supernatant. Nuclear doxorubicin fluorescence is now I-I2-I3, while total nuclear doxorubicin (fluorescent plus non-fluorescent) is Io-I3. Fluorescent doxorubicin as a percentage of the total amount of doxorubicin in the nuclei can thus be calculated from:
[(II-12)-131/[Io-13] x 100. The ratio was 8.5 ± 1.4% (mean ± s.e.m. of two independent experiments, each determined in triplo, for nuclei of both cell lines. No quenching of doxorubicin in non-nuclear cellular compartments was assumed to occur (Tarasiuk et al., 1989) .
Results
Relationship between IC50 and drug accumulation at IC50 As for many MDR cells with P-glycoprotein, verapamil caused a dose-dependent decrease of IC50 in the human nonsmall cell lung cancer MDR cells SW-1573/1R500 as illustrated in Figure 1 (ordinate). Doxorubicin resistance could not be reversed completely (residual level of resistance was about 7) at least partly because concentrations of verapamil higher than 128 gM could not be used due to unacceptable toxicity in the 24 h incubation assay with verapamil. When cellular doxorubicin accumulation was determined in a 2 h incubation assay at the actual IC50 values obtained (e.g. 32 tLM doxorubicin with no verapamil present and 1 tLM doxorubicin with 24 ,UM verapamil present), a linear relationship was found when IC50 values were plotted on a logarithmic scale against cellular doxorubicin amounts measured at these IC50 values (Figure 1 ). This shows that reversal of resistance can be described by a function of the type
in which c is a constant and doxi is the cellular amount of doxorubicin at each IC50 value. The figure shows that (i) intracellular doxorubicin is very ineffective in inhibiting cell growth in SW-1573/1R500 cells when no verapamil is present (490 pmol 10-6 cells were necessary to reach IC50 compared to about 14 pmol 10 6 cells in the parent cell line SW-1573) and (ii) verapamil drastically increases the efficacy of doxorubicin in the MDR cells (only about 80 pmol 106 cells are necessary to reach IC50 when 128 .LM verapamil is present). For the human breast cancer cell line MCF-7ADR similar results were obtained ( Figure 2 ). The ability of verapamil to increase the efficacy of doxorubicin must be added to its well-known action on drug accumulation perse at a fixed doxorubicin concentration and which is illustrated in Figure  3 (Figure 6 ).
The minimal cellular amount of doxorubicin necessary to reach IC50 was 8 pmol 10-6 cells as found for SW-1573 cells in the presence of verapamil (see Figure 6 ). Since the majority of doxorubicin in sensitive cells is present in the nucleus (Seeber et al., 1980) , the nuclear amount of doxorubicin necessary to reach IC50 was approximately 8 pmol 106 cells.
For the SW-1573/1R500-0 cells the curve did not cross the coordinates found for the sensitive SW-1573 cells (Figure 6 ). When, however, the intracellular doxorubicin amounts at IC50 were corrected for the cytoplasmic volume (which is relatively large in this cell line; see Table I ) in a way described under Materials and methods and in the legends of Figure 6, (Schuurhuis et al., 1989a) . We now have measured similar resistance-related and/or verapamil-induced changes in the ratio nuclear doxorubicin fluorescence and cytoplasmic doxorubicin fluorescence in human MDR cancer cell lines (Table  II) . Figure 7 illustrates doxorubicin fluorescence distribution in the 2780 ovarian cancer cell lines in the presence of different concentrations of verapamil. In parental A2780 cells relatively little fluorescence is present in the cytoplasm (Figure 7a ). This situation is not altered when verapamil is used (Figure 7b ). In contrast, resistant 2780AD cells contain a relatively large fraction of the total cellular fluorescence in the cytoplasm, either as a diffuse Golgi-like cloud or in a punctuate pattern throughout the cytoplasm (Figure 7c ). Verapamil in increasing concentrations increases the percentage of cells with preferential nuclear fluorescence localisation (compare situation in the absence of verapamil in Figure 7c with d and e, which illustrate the effects of 4 and 8 gM verapamil, respectively). In the presence of 128 LM of verapamil almost all cells showed preferential nuclear fluorescence (illustrated in Figure 7f ). the other hand the photographs in Figure 9 also illustrate that the nuclear doxorubicin fluorescence, measured at equitoxic concentrations, may vary much less over the whole range of reversal of resistance. As a result of these processes total cellular fluorescence was much higher in CHRC5 cells without verapamil than in AUXB1 cells without verapamil (factor > 13), when measured under equitoxic conditions (700 liM and 1 lIM, respectively, corresponding to the Figures 9f and a, respectively) and when using the method that enabled direct comparison of fluorescence signals (see Materials and methods under 'quantification of drug distribution with laser scan microscopy'). This difference was reduced to a factor 9.7 ± 4.3 (n = 3) under conditions illustrated in Figure 9e . A further reduction to 2.7 ± 1.4 (n = 3) was found using 8 JLM doxorubicin plus 4 iLM verapamil (Figure 9d ). At complete reversal of resistance total cellular fluorescence was only a factor 1.2 ± 0.3 (n = 3) higher than in AUXB1 cells.
No quenching of cytoplasmic fluorescence has been assumed to occur (see Materials and methods; Tarasiuk et al., 1989) . Recently, however, a possible concentrationdependent quenching of daunorubicin in denucleated cells has been reported (Slapak et al., 1992) . Consequently, at the higher drug concentrations (e.g. > 3 ILM in Figure 8) Unfortunately, determination of N/C ratios was inaccurate especially at higher levels of resistance because part of the cytoplasmic fluorescence overlapped the nuclear fluorescence. As a result the N value in the N/C ratio, and thereby the calculated total nuclear doxorubicin amounts, will be overestimated at the higher levels of resistance. Nevertheless Figure  8 shows that at complete reversal of resistance (32 IM verapamil) the calculated nuclear drug amounts are the same as in AUXB1 cells.
Discussion
From the literature it appears that there is almost consensus about the fact that multidrug resistance is multifactorial. For example, the factors mentioned to contribute to anthracycline or VP-16 resistance in MDR cells include decreased drug accumulation, caused by changes in drug influx and/or drug efflux (Bradley et al., 1988) and mostly parallelled by changes in the intracellular distribution of the drug Gervasoni et al., 1991; Gigli et al., 1989; Hindenburg et al., 1987 Hindenburg et al., , 1989 Schuurhuis et al., 1989a Schuurhuis et al., , 1991 Willingham et al., 1986) , changes in topoisomerase II activity/levels (Beck, 1989) or alterations in drug activation or in the capacity to detoxify reactive druginduced oxygen-derived free radicals (Sinha & Mimnaugh, 1990 (Fairchild et al., 1987; . The decrease in drug efficacy might in principle be caused by factors such as alterations of glutathione transferase activity as mentioned above. However, an agent like verapamil, known for its potent stimulation of drug accumulation in such P-glycoprotein-containing cells (Bradley et al., 1988; Ford et al., 1988; Politi et al., 1990) Figure 5a (at doxorubicin concentrations <1 1AM) is indicated ( .... ). Dx, doxorubicin; Vp, verapamil. In the inset it is shown that at verapamil concentrations <21AM deviations from linearity occur in SW-1573/lR500-00 cells similar to those seen at low verapamil concentrations in Figure 5. reversal of resistance by verapamil would have been caused solely by stimulation of drug accumulation, [doxi at IC50] would have been constant in the presence or absence of different concentrations of verapamil (line I in Figure IOA) Figure IOA ). With this in mind the shape of the curves as shown in the Figures 5 and 6 can easily be explained assuming that verapamil shows both effects at residual resistance levels of > 17 (SW-1573/1R500), >6 (MCF-7ADR) and >7.5 (SW-1573/lR500-0), while at residual resistance levels of [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] (SW-1573/lR500), 4-6 (MCF-7ADR) and 2-7.5 (SW-1573/ 1 R500-0) it acts almost exclusively via its accumulationindependent effect.
In the 7.4-fold resistant SW-1573/1R50 cells, which do not express P-glycoprotein , an accumulation defect of 1.6 was found (not shown), indicating that emergence of resistance in these cells occurred both via a decrease of drug accumulation and a decrease of drug efficacy. This is compatible with the observation that a curve which would include the coordinates of the origin, SW-1573 (minus verapamil) and SW-1573/1R50 (minus verapamil) (see -test) . N/C ratios were determined at IC50 values of doxorubicin except for the sensitive cells or when verapamil (Vp) was used (in those cases 2 M doxorubicin was used since at lower concentrations background noise became too high). N/C ratios are independent of doxorubicin concentration in a large range of drug concentrations (De Lange et al., 1992) , suggesting that this is also the case at concentrations lower than 2pM.
(compare with line II in Figure lOA and B. This has been confirmed in accumulation experiments performed at a fixed (0.5 ;iM) doxorubicin concentration which revealed no accumulation defect (not shown).
Continuous exposure of SW-1573/2R30 cells to doxorubicin led to isolation of SW-i 573/2R50 cells, which are of a non-P-glycoprotein MDR phenotype Kuiper et al., 1990) and after prolonged exposure to cells with an increased mdr-I mRNA and P-glycoprotein expression (Kuiper et al., 1990) . Similar results have been found for murine erythroleukaemia cells (Slapak et al., 1990) . It could thus be that doxorubicin resistance in low level MDR non-Pglycoprotein lung cancer cells as well as doxorubicin resistance of early selected cells of the high level MDR P-glycoprotein cell lines MCF-7ADR and 2780AD, is caused, at least partly, by the same P-glycoprotein-independent phenotypic change that occurs in P-glycoprotein-mediated resistance, i.e. a change in intracellular drug efficacy, which would, at least partly, be caused by a change in subcellular drug distribution.
In the present study it is shown that a partial reversal of doxorubicin resistance was accomplished in human MDR cells which was accompanied by a partial reversal of N/C ratio changes (Table II) . Complete reversal of doxorubicin resistance in CHRC5 P-glycoprotein/MDR Chinese hamster ovarian cells to parental AUXB1 levels was accompanied by a complete reversal of the drug accumulation defect as well as the drug distribution change (Schuurhuis et al., 1989a) . The consequence of these findings would be that it is mainly if not only the nuclear concentration of drug which determines sensitivity/resistance. For CHRC5 cells we confirmed this relationship (Figures 8, 9 ). It cannot be excluded, however, that verapamil acts via a mechanism comprising increment of nuclear doxorubicin efficacy. This mechanism of resistance reversal might prevail in non-P-glycoprotein MDR cells. The fact that considerable decrease of doxorubicin resistance in such cells by verapamil is possible with only small concomitant changes of drug accumulation or drug distribution (this paper; Schuurhuis et al., 1991) , are in favour of this idea. The results presented in the present paper for P-glycoprotein MDR cells are nevertheless in agreement with a paper of Gigli and colleagues, who did not study verapamil effects, but, making use of spectral properties of doxorubicin, showed that nuclear concentrations of doxorubicin were not significantly different at equitoxic drug concentrations in sensitive and resistant K562 human leukaemia cells (Gigli et al., 1989) . Also, in a study comparing cellular doxorubicin accumulation, cytotoxicity and DNA lesions in sensitive and multidrug-resistant human myeloma cells, Bel- Figure 9 .
damage in the resistant cells was also less under these conditions (compare Bellamy et al., 1988a and b) . This is in good agreement with the observation that N/C ratios are lower in these resistant cells (De Lange et al., 1992; Broxterman et al., 1990 ). This suggests, as outlined extensively in the present paper, that higher cellular concentrations are needed in the resistant cells in order to obtain the same nuclear concentrations as in sensitive cells. It has to be stated that other reversing agents behave in a way similar to verapamil: bepridil, Ro 11-2933/001 and Cremophor EL have been tested as to this (Schuurhuis et al., 1989a (Schuurhuis et al., , 1990a . None of the modifiers, even at high concentrations, was able to overcome completely accumulation defects in human MDR cells (see e.g. Schuurhuis et al., 1990b) . Verapamil has been used mainly because it is less toxic than several other reversing agents and because it is the most widely studied reverter. Figure 9 Subcellular doxorubicin fluorescence distribution in the presence or absence of verapamil at equitoxic concentrations in CHRC5 and AUXBI cells. Adhered cells were incubated for 2 h at 37°C with combinations of different concentrations of doxorubicin and verapamil, as specified below, which all resulted in the same growth-inhibition. Doxorubicin concentrations used were in all cases 2.5 times higher than the IC,0 values, shown in Figure 7 (Willingham et al., 1986) , human myeloma and human leukaemia (Gigli et al., 1989) cells show changes in subcellular drug distribution in addition to changes in cellular drug accumulation. It is therefore tempting to speculate that the relatively simple explanation for doxorubicin resistance in P-glycoprotein/MDR cells, including the two factors depicted in this paper, is generally applicable.
It has been speculated that changes in free radical detoxifying enzymes such as glutathione transferase and glutathione peroxidase contribute to doxorubicin resistance in Pglycoprotein/MDR MCF-7ADR cells Cowan et al., 1986; Sinha et al., 1987; Sinha & Mimnaugh, 1990 (Broxterman et al., 1988; CanoGauci & Riordan, 1987; Yusa & Tsuruo, 1989) . Verapamil also had no effect on glutathione peroxidase activity (Batist et al., 1991) . Lastly, it has been found that transfection of the gene encoding for glutathione transferase did not confer resistance to doxorubicin (Moscow et al., 1989) . Since changes in expression of enzymes suggested to be involved in detoxification of xenobiotics apparently are not involved in doxorubicin resistance we speculate that transfection of the gene encoding for glutathione peroxidase will not confer resistance to doxorubicin in MCF-7 or other parental cell lines.
Upon the mechanism by which MDR cells acquire an altered subcellular drug distribution can only be speculated. Small amounts of P-glycoprotein present on the membranes of cytoplasmic vesicles (Willingham et al., 1987) might force the drug into the vesicles. Alternatively, a drop in vesicular pH, probably parallelling an increase of the cytoplasmic pH under certain conditions Thiebaut et al., 1990) or an increase of the vesicular compartment (Sehested et al., 1987) might explain higher drug accumulation in cytoplasmic compartments, resulting in decreased N/ C ratios.
In conclusion, the results presented in this paper show that, at least in P-glycoprotein MDR cells, changes in drug accumulation together with changes in subcellular drug distribution largely account for doxorubicin resistance, thereby excluding the need to postulate additional mechanisms for these cell lines.
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